Biology Reference
In-Depth Information
Gondo Y, Porteous DJ, Roder JC (2007) Behavioral phenotypes of Disc1 missense mutations
in mice. Neuron 54:387-402
Conti M, Iona S, Cuomo M, Swinnen JV, Odeh J, Svoboda ME (1995) Characterization of
a hormone-inducible, high affinity adenosine 3
0
-5
0
-cyclic monophosphate phosphodiesterase
from the rat Sertoli cell. Biochemistry 34:7979-7987
Cooper DM (2003) Regulation and organization of adenylyl cyclases and cAMP. Biochem J
375:517-529
Davis RL, Takayasu H, Eberwine M, Myres J (1989) Cloning and characterization of mammalian
homologs of the Drosophila dunce + gene. Proc Natl Acad Sci U S A 86:3604-3608
Day JP, Dow JA, Houslay MD, Davies SA (2005) Cyclic nucleotide phosphodiesterases in
Drosophila melanogaster. Biochem J 388:333-342
DeMarch Z, Giamp` C, Patassini S, Bernardi G, Fusco FR (2008) Beneficial effects of rolipram in
the R6/2 mouse model of Huntington's disease. Neurobiol Dis. Jun;30(3):375-387 Epub 2008
Mar 7. PMID:18424161
Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Berner P, Simhandl C, Wolf R, Gerlach W,
Jaklitsch H, Sastre-y-Hernandez M et al (1992) A multicenter double-blind study of three
different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major
depressive disorder. Neuropsychobiology 26:59-64
Fujimaki K, Morinobu S, Duman RS (2000) Administration of a cAMP phosphodiesterase
4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neurop-
sychopharmacology 22:42-51
Giembycz MA (2002) Development status of second generation PDE4 inhibitors for asthma and
COPD: the story so far. Monaldi Arch Chest Dis 57:48-64
Giembycz MA (2005) Phosphodiesterase-4: selective and dual-specificity inhibitors for the ther-
apy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2:326-333, discussion
340-321
Giembycz MA (2006) An update and appraisal of the cilomilast Phase III clinical development
programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol 62:138-152
Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O (2004) Persistent improvement
in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.
J Clin Invest 114:1624-1634
Hatzelmann A, Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel
PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279
Heaslip RJ, Evans DY (1995) Emetic, central nervous system, and pulmonary activities
of rolipram in the dog. Eur J Pharmacol 286:281-290
Hebenstreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U, Sastre-y-Hernandez M,
Schony W, Schratzer M, Soukop W et al (1989) Rolipram in major depressive disorder: results
of a double-blind comparative study with imipramine. Pharmacopsychiatry 22:156-160
Henkel-Tigges J, Davis RL (1990) Rat homologs of the Drosophila dunce gene code for cyclic
AMP phosphodiesterases sensitive to rolipram and RO 20-1724. Mol Pharmacol 37:7-10
Hirose R, Manabe H, Nonaka H, Yanagawa K, Akuta K, Sato S, Ohshima E, Ichimura M (2007)
Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the
high-affinity rolipram binding site in Suncus murinus brain. Eur J Pharmacol 573:93-99
Hoffmann R, Wilkinson IR, McCallum JF, Engels P, Houslay MD (1998) cAMP-specific phos-
phodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition
triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.
Biochem J 333(Pt 1):139-149
Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD (1999) The MAP kinase ERK2
inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at
Ser579. EMBO J 18:893-903
Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol
69:249-315
